American Banking and Market News logo

The Latest Headlines at American Banking and Market News

Image about Levi Strauss & Co. (NYSE:LEVI) Price Target Raised to $22.00 at Telsey Advisory Group

Levi Strauss & Co. (NYSE:LEVI) Price Target Raised to $22.00 at Telsey Advisory Group

Levi Strauss & Co. (NYSE:LEVI – Free Report) had its price target lifted by Telsey Advisory Group from $18.00 to $22.00 in a report issued on Wednesday, MarketBeat.com reports. The firm currently has an outperform rating... More of this article »
Image about KB Home (NYSE:KBH) Price Target Increased to $70.50 by Analysts at JPMorgan Chase & Co.

KB Home (NYSE:KBH) Price Target Increased to $70.50 by Analysts at JPMorgan Chase & Co.

KB Home (NYSE:KBH – Free Report) had its price objective boosted by JPMorgan Chase & Co. from $68.50 to $70.50 in a research note published on Wednesday morning, Benzinga reports. The brokerage currently has a neutral rating... More of this article »
Image about Travere Therapeutics’ (TVTX) “Neutral” Rating Reaffirmed at Guggenheim

Travere Therapeutics’ (TVTX) “Neutral” Rating Reaffirmed at Guggenheim

Guggenheim reissued their neutral rating on shares of Travere Therapeutics (NASDAQ:TVTX – Free Report) in a research report released on Wednesday morning, MarketBeat Ratings reports. A number of other brokerages also recently... More of this article »
Image about Delcath Systems (NASDAQ:DCTH) Price Target Increased to $20.00 by Analysts at HC Wainwright

Delcath Systems (NASDAQ:DCTH) Price Target Increased to $20.00 by Analysts at HC Wainwright

Delcath Systems (NASDAQ:DCTH – Free Report) had its price objective upped by HC Wainwright from $18.00 to $20.00 in a report published on Wednesday, Benzinga reports. They currently have a buy rating on the stock. Delcath Systems... More of this article »
Image about Genmab A/S (NASDAQ:GMAB) Receives “Buy” Rating from HC Wainwright

Genmab A/S (NASDAQ:GMAB) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Genmab A/S (NASDAQ:GMAB – Free Report) in a report released on Wednesday, Benzinga reports. HC Wainwright currently has a $50.00 target price on the stock. Several other equities... More of this article »
Image about Lucid Diagnostics (NASDAQ:LUCD) Given Buy Rating at Needham & Company LLC

Lucid Diagnostics (NASDAQ:LUCD) Given Buy Rating at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Lucid Diagnostics (NASDAQ:LUCD – Free Report) in a research note released on Wednesday morning, Benzinga reports. They currently have a $2.50 target price on... More of this article »
Image about Syndax Pharmaceuticals’ (SNDX) “Buy” Rating Reaffirmed at HC Wainwright

Syndax Pharmaceuticals’ (SNDX) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. The brokerage currently has a $41.00 target price... More of this article »
Image about Intuit (NASDAQ:INTU) Price Target Raised to $720.00 at KeyCorp

Intuit (NASDAQ:INTU) Price Target Raised to $720.00 at KeyCorp

Intuit (NASDAQ:INTU – Free Report) had its price objective boosted by KeyCorp from $700.00 to $720.00 in a report released on Wednesday morning, Benzinga reports. The brokerage currently has an overweight rating on the software... More of this article »
Image about Western Digital (NASDAQ:WDC) Coverage Initiated by Analysts at Evercore ISI

Western Digital (NASDAQ:WDC) Coverage Initiated by Analysts at Evercore ISI

Evercore ISI assumed coverage on shares of Western Digital (NASDAQ:WDC – Free Report) in a report released on Wednesday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $80.00 price objective on... More of this article »
Image about Kiora Pharmaceuticals (NASDAQ:KPRX) Given “Buy” Rating at HC Wainwright

Kiora Pharmaceuticals (NASDAQ:KPRX) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Kiora Pharmaceuticals (NASDAQ:KPRX – Free Report) in a report released on Wednesday, Benzinga reports. Kiora Pharmaceuticals Stock Performance NASDAQ KPRX opened at $0.62... More of this article »
Image about Sirius XM (NASDAQ:SIRI) Given New $6.50 Price Target at Benchmark

Sirius XM (NASDAQ:SIRI) Given New $6.50 Price Target at Benchmark

Sirius XM (NASDAQ:SIRI – Free Report) had its price objective lowered by Benchmark from $7.00 to $6.50 in a research note issued to investors on Wednesday morning, Benzinga reports. The brokerage currently has a buy rating on... More of this article »
Image about Linde (NASDAQ:LIN) Lowered to Neutral at UBS Group

Linde (NASDAQ:LIN) Lowered to Neutral at UBS Group

UBS Group downgraded shares of Linde (NASDAQ:LIN – Free Report) from a buy rating to a neutral rating in a research report released on Wednesday morning, MarketBeat Ratings reports. The brokerage currently has $510.00 price objective... More of this article »
Image about Royal Gold (NASDAQ:RGLD) Upgraded to “Outperform” at BMO Capital Markets

Royal Gold (NASDAQ:RGLD) Upgraded to “Outperform” at BMO Capital Markets

BMO Capital Markets upgraded shares of Royal Gold (NASDAQ:RGLD – Free Report) (TSE:RGL) from a market perform rating to an outperform rating in a research note published on Wednesday morning, Marketbeat.com reports. The firm... More of this article »
Image about Gain Therapeutics (NASDAQ:GANX) Given Buy Rating at Chardan Capital

Gain Therapeutics (NASDAQ:GANX) Given Buy Rating at Chardan Capital

Chardan Capital restated their buy rating on shares of Gain Therapeutics (NASDAQ:GANX – Free Report) in a report issued on Wednesday morning, Benzinga reports. They currently have a $6.00 price target on the stock. Separately,... More of this article »
Image about CSG Systems International (NASDAQ:CSGS) Coverage Initiated by Analysts at Royal Bank of Canada

CSG Systems International (NASDAQ:CSGS) Coverage Initiated by Analysts at Royal Bank of Canada

Royal Bank of Canada began coverage on shares of CSG Systems International (NASDAQ:CSGS – Free Report) in a report issued on Wednesday morning, MarketBeat.com reports. The brokerage issued an outperform rating and a $61.00 target... More of this article »